Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. [electronic resource]
Producer: 20160505Description: 1621-34 p. digitalISSN:- 1533-4406
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boron Compounds -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Double-Blind Method
- Exanthema -- chemically induced
- Glycine -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Lenalidomide
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Proportional Hazards Models
- Quality of Life
- Thalidomide -- administration & dosage
- Thrombocytopenia -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.